September 8, 2006European Heart Journal
Renin angiotensin blockade in heart failure with preserved ejection fraction: the signal gets stronger
Key result
Renin-angiotensin blockade in heart failure with preserved ejection fraction may reduce heart failure hospitalizations, though trials like PEP-CHF suffered from low power and event rates.
Why the study?
Does renin-angiotensin system blockade reduce death or heart failure hospitalization in patients with heart failure with preserved ejection fraction?
Population
Individuals with heart failure with preserved ejection fraction (HF-PEF)
Comparison
Renin-angiotensin system blockade vs Placebo
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
Despite methodological challenges and lack of definitive mortality benefit in trials to date, renin-angiotensin blockade likely reduces heart failure hospitalizations in patients with HF-PEF.
Structured PICO
Does renin-angiotensin system blockade reduce death or heart failure hospitalization in patients with heart failure with preserved ejection fraction?
P
Population
Individuals with heart failure with preserved ejection fraction (HF-PEF)
I
Intervention
Renin-angiotensin system (RAS) blockade (e.g., perindopril)
C
Comparator
Placebo
O
Outcome
Composite outcome of death or HF-related hospitalizationcomposite
Despite methodological challenges and lack of definitive mortality benefit in trials to date, renin-angiotensin blockade likely reduces heart failure hospitalizations in patients with HF-PEF.
Limitations
- Low recruitment and low event rates resulting in a considerable loss of statistical power
- High rate of study drug discontinuation and open-label ACE-inhibitor use
- Low recruitment
- Low event rates
- High rate of study drug discontinuation
- Open-label ACE-inhibitor use
Cite This Study
John J.V. McMurray (2006) conducted an editorial in Heart failure with preserved ejection fraction (HF-PEF). Renin angiotensin blockade vs. Placebo was evaluated on Death or HF-related hospitalization. Renin-angiotensin blockade in heart failure with preserved ejection fraction may reduce heart failure hospitalizations, though trials like PEP-CHF suffered from low power and event rates.